NEUCHATEL, Zwitserland–(BUSINESS WIRE)– Masimo heeft vandaag de marktlancering van zijn Pronto ® Pulse CO-Oximeter ® met nieuwe SpHb ® Spot Check-technologie buiten de Verenigde Staten aangekondigd. De nieuwe Pronto heeft SET™ -technologie voor niet-invasieve deelwaarneming van het hemoglobinegehalte, zuurstofsaturatie, pols, en de perfusie-index.
Naast deze SpHb-technologie heeft Masimo ook de kleine, herbruikbare sensor rainbow ® DCI ® op de markt gebracht voor gebruik in combinatie met de Pronto. De DCI-mini is een universele sensor voor patiënten met een gewicht boven de 3 kilogram, waardoor Pronto nog veelzijdiger wordt.
Masimo Announces Full Market Release of Next Generation SpHb® Spot Check Pronto®
NEUCHATEL, Switzerland–(BUSINESS WIRE)– Masimo (NASDAQ: MASI) announced today the full market release outside the U.S. of the Pronto ® Pulse CO-Oximeter ® with Next Generation SpHb ® Spot Check technology. Next Generation Pronto features rainbow SET™ technology, for noninvasive spot checking of total hemoglobin (SpHb), oxygen saturation (SpO 2), pulse rate (PR), and perfusion index (PI).
This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20160608005479/en/
Pronto Pulse CO-Oximeter with Next Generation SpHb and rainbow DCI-mini Reusable Sensor (Photo: Business Wire)
In addition to the Next Generation SpHb technology, Masimo has also released the rainbow ® DCI ®-mini reusable sensor to accompany the Pronto. The DCI-mini is a universal sensor usable on patients greater than 3 kg, making Pronto an even more versatile solution.
The Next Generation SpHb technology in Pronto offers motion tolerance and a 40% reduction in time to display SpHb results. Field accuracy has been improved in the range of 6 to 11 g/dL, and is comparable to certain portable invasive point of care devices.
“This is a significant enhancement to the noninvasive measurement we introduced 7 years ago,” stated Joe Kiani, Founder and CEO of Masimo. “Since then, all of the clinical outcome studies we’re aware of on our continuous SpHb technology have been positive, 1-3 which is something that couldn’t be said for standard pulse oximetry before the introduction of Masimo SET SpO 2. We will continue to improve SpHb until it has the same measure-through motion and low perfusion performance as our SET SpO 2 technology.”
An upgrade program will be available for qualified existing Pronto customers. Pronto with Next Generation SpHb and the DCI-mini reusable sensor have not received FDA 510(k) clearance and are not currently available for sale in the United States.
@MasimoInnovates | #Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect (MOC-9) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo’s Pronto® Pulse CO-Oximeter®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including Masimo’s Pronto Pulse CO-Oximeter, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.